Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
Both vinorelbine and docetaxel are effective as single agents in non-small cell lung cancer, with response rates of 25% to 30%. Several in vitro and in vivo models demonstrate schedule-dependent synergy between these agents. In phase II clinical trials of the combination, response rates and median survivals ranged from 27% to 49% and 5 to 9 months, respectively. Common toxicities included neutropenia, febrile neutropenia, and mucositis. With prolonged therapy, severe onycholysis and eye irritation also have been noted. In conclusion, docetaxel and vinorelbine are active together and offer one alternative to cisplatin-based therapy for patients with adequate performance status.
Krug
L M
LM
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Miller
V A
VA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives; D016019:Survival Analysis; D043823:Taxoids; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
D043823:Taxoids; D000077143:Docetaxel; D014747:Vinblastine; D017239:Paclitaxel; D000077235:Vinorelbine